Business context and reporting period
The supplied filing is Synaptogenix, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2024, not a filing identified as TAO Synergies Inc. Investors should confirm the issuer before relying on this summary. Synaptogenix is a development-stage biopharmaceutical company focused on Bryostatin-1, principally for Alzheimer’s disease (AD), and is also evaluating other indications.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 or prior period |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $0.61 million | $0.88 million |
| General and administrative expense | $1.08 million | $2.04 million |
| Total operating expense | $1.69 million | $2.92 million |
| Other income | $1.48 million | $1.21 million |
| Net loss | $0.21 million | $1.71 million |
| Net loss attributable to common stockholders | $0.43 million | $1.98 million |
| Basic and diluted loss per share | $0.41 | $6.59 |
| Cash used in operating activities | $1.83 million | $1.70 million |
| Cash and cash equivalents at March 31 | $26.33 million | $28.66 million at Dec. 31, 2023 |
| Total assets / total liabilities at March 31 | $29.40 million / $6.52 million | $31.11 million / $5.53 million at Dec. 31, 2023 |
There is no meaningful revenue margin to report. The company reported no conventional debt balance in the presented balance sheet; liabilities include $6.02 million accrued for Series B preferred installment payments, up from $3.40 million at year-end. Working capital was $22.53 million, down from $26.26 million. Cash flow from investing activities was a $0.50 million outflow, reflecting a purchase of available-for-sale debt securities; financing cash flow was zero.
Material changes versus the prior comparable period
- Operating expenses fell 42% year over year, largely as AD trials concluded or were discontinued and 2023 general and administrative costs included substantially higher stock-based compensation and professional fees.
- Net loss declined by $1.51 million, mainly due to lower operating expenses and higher other income. Other income included non-cash fair-value gains of $0.97 million on the embedded derivative and $0.06 million on warrant liabilities.
- Operating cash use increased by $0.14 million despite the smaller net loss, reflecting working-capital movements and lower non-cash compensation and consulting-stock adjustments.
- During the quarter, the company issued 106,126 shares to redeem $3.00 million of Series B preferred stock and $87,500 of accrued dividends. It also recorded $2.46 million of preferred-stock accretion and a $0.13 million deemed dividend.
Outlook, commentary, risks and unusual items
- Management estimated that approximately $25.9 million of cash and cash equivalents at the report date would fund projected operating requirements and financial commitments for at least 12 months. The company expects to need additional capital for further development, including work beyond the ongoing Bryostatin-1 program; financing may be dilutive, unavailable, or subject to restrictive terms.
- The extended confirmatory Phase 2 AD study was completed in December 2023 but did not meet its primary endpoint. Earlier reported analyses found some statistically significant secondary and exploratory results in a subgroup with more advanced, severe AD; these do not change the failed primary endpoint.
- A Phase 1 multiple sclerosis collaboration with Cleveland Clinic is underway; the company reported $0.38 million paid and expensed in Q1 and estimated total collaboration costs of about $2.0 million. The Fragile X IND is on FDA clinical hold pending further pharmacokinetic and pharmacodynamic analyses. The company is evaluating whether and how to advance that program.
- Bryostatin supply is a material development risk: existing NIH supply arrangements are insufficient for all trials required for potential approval, and additional supply agreements or another source would be needed. The company estimates about $1.5 million to initiate production of sufficient synthetic bryostatin and is evaluating production alternatives.
- On April 4, 2024, the company effected a 1-for-25 reverse stock split; Nasdaq subsequently informed the company on April 22 that it had regained minimum-bid-price compliance. These are post-quarter events.
- Disclosure controls and procedures were deemed ineffective as of March 31, 2024 because of material weaknesses involving segregation of duties, period-end financial reporting and documentation, and IT general controls. Management nevertheless stated that the financial statements fairly present the company’s financial condition and results.
- The company disclosed uncapped reciprocal indemnification obligations related to its spin-off and tax matters, although it reported no related claims as of the reporting date. It also cautioned that a determination that the spin-off was taxable could create significant tax liabilities.
Most important facts for investors to verify
- Confirm issuer identity: the provided filing names Synaptogenix, Inc. (ticker SNPX), while the request metadata names TAO Synergies Inc.
- Review the failed AD primary endpoint, the subgroup analyses, and the company’s specific plans and funding for subsequent clinical work.
- Assess the Series B preferred redemption schedule, accrued installment liability, potential cash-payment requirements, and dilution from share settlements and warrants.
- Verify liquidity assumptions against the expected clinical, manufacturing, and preferred-stock commitments, and the need and availability of additional capital.
- Review the status of the Fragile X clinical hold, MS trial, and reliable supply of Bryostatin-1.
- Assess remediation of the disclosed control weaknesses. Also reconcile reported common shares outstanding of 1,085,237 at March 31 with 1,233,230 reported at May 13, considering the reverse split and post-quarter issuances.